Dergiler / Turkish journal of nephrology (Online) / 2022 / Cilt: 31 - Sayı: 3

Emerging Novel Etiology for Thrombotic Microangiopathies: COVID-19 Infection

Sayfa
265–268
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This is the first case reporting the appearance of stage 3 acute kidney injury in thrombotic thrombocytopenic purpura due to coronavirus disease 2019 infection after a window period of 1 month and successful treatment with only steroids.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The novel and worldwide spread of coronavirus disease 2019 has important thrombotic complications, making it necessary to treat it with low-molecular-weight heparin.
📊
Temel Bulgular & Veri:However, though it is very rare, it should be kept in mind that coronavirus disease 2019 infection might be complicated by thrombotic thrombocytopenic purpura, resulting in severe thrombocytopenia which makes heparin use contraindicated.
💡
Sonuç & Katkı:This is the first case reporting the appearance of stage 3 acute kidney injury in thrombotic thrombocytopenic purpura due to coronavirus disease 2019 infection after a window period of 1 month and successful treatment with only steroids.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

The novel and worldwide spread of coronavirus disease 2019 has important thrombotic complications, making it necessary to treat it with low-molecular-weight heparin. However, though it is very rare, it should be kept in mind that coronavirus disease 2019 infection might be complicated by thrombotic thrombocytopenic purpura, resulting in severe thrombocytopenia which makes heparin use contraindicated. The complications of thrombotic thrombocytopenic purpura have been elucidated after this pandemic infection. We report a case of acquired thrombotic thrombocytopenic purpura due to late hematological manifestation of coronavirus disease 2019 infection. A 47-year-old male patient who developed microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (stage 3) with macroalbuminuria was diagnosed with thrombotic thrombocytopenic purpura based on very low plasma ADAMTS13 activity and borderline ADAMTS13 inhibitor level 4 weeks after coronavirus disease 2019 infection detected by positive nucleic acid amplification test (reverse-transc ription polymerase chain reaction). Coronavirus disease 2019 infection usually leads to thrombotic events, making it necessary to treat it with low-molecular-weight heparin. However, even though it is very rare, it should be kept in mind that coronavirus disease 2019 infection might be complicated by thrombotic thrombocytopenic purpura, resulting in severe thrombocytopenia, which makes heparin use contraindicated. This is the first case reporting the appearance of stage 3 acute kidney injury in thrombotic thrombocytopenic purpura due to coronavirus disease 2019 infection after a window period of 1 month and successful treatment with only steroids.

🔖

Bu Makaleye Atıf Yap

GÜVERCİN, B., KAYNAR, K., VAROL, G., TURAN, N., PEKTAŞ, A. (2022). Emerging Novel Etiology for Thrombotic Microangiopathies: COVID-19 Infection. Turkish journal of nephrology (Online), Cilt: 31 - Sayı: 3, 265–268. https://ajindex.com/articles/612824

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Dixon BP, Gruppo RA. Atypical hemolytic uremic syndrome. Pediatr Clin North Am. 2018;65(3):509-525. [CrossRef] 2. Henry BM, Benoit SW, de Oliveira MHS, Lippi G, Favaloro EJ, Benoit JL. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. Int J Lab Hematol. 2021;43(suppl 1):129-136. [CrossRef] 3. George JN, Cuker A. Diagnosis of immune TTP. UpToDate.com; 2022. Available at: https://www.uptodate.com/contents/diagno sis-of-immune-ttp? Accessed 09/03/2022. 4. Albiol N, Awol R, Martino R. Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19. Ann Hematol. 2020;99(7):1673-1674. [CrossRef] 5. Tehrani HA, Darnahal M, Vaezi M, Haghighi S. COVID-19 associated thrombotic thrombocytopenic purpura (TTP); a case series and mini-review. Int Immunopharmacol. 2021;93:107397. [CrossRef] 6. Al-Ansari RY, Bakkar M, Abdalla L, Sewify K. Critical care COVID-19 patient with a picture of thrombotic thrombocytopenic purpura. Eur J Case Rep Intern Med. 2020;7(12):002143. [CrossRef] 7. Altowyan E, Alnujeidi O, Alhujilan A, Alkathlan M. COVID-19 presenting as thrombotic thrombocytopenic purpura (TTP). BMJ Case Rep. 2020;13(12):e238026. [CrossRef] 8. Beaulieu MC, Mettelus DS, Rioux-Massé B, Mahone M. Thrombotic thrombocytopenic purpura as the initial presentation of COVID19. J Thromb Haemost. 2021;19(4):1132-1134. [CrossRef] 9. Nicolotti D, Bignami EG, Rossi S, Vezzani A. A case of thrombotic thrombocytopenic purpura associated with COVID-19. J Thromb Thrombolysis. 2021;52(2):468-470. [CrossRef] 10. Darnahal M, Azhdari Tehrani H, Vaezi M, Haghighi S. Covid-19 and thrombotic thrombocytopenic purpura: a case report. Int J Hematol Oncol Stem Cell Res. 2021;15(1):72-74. [CrossRef] 11. Aminimoghaddam S, Afrooz N, Nasiri S, Motaghi Nejad O, Mahmoudzadeh F. A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report. J Med Case Rep. 2021;15(1):104. [CrossRef] 12. Galindo-Calvillo CD, Rodríguez-Roque CS, Gómez-De León A, Tarín-Arzaga L, Gómez-Almaguer D. Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review. Transfus Apher Sci. 2021;60(3):103107. [CrossRef] 13. Dalkıran T, Kandur Y, Kara EM, Dağoğlu B, Taner S, Öncü D. Thrombotic microangiopathy in a severe pediatric case of COVID19. Clin Med Insights Pediatr. 2021;15:1179556521